Diagnostic aids in the screening of oral cancer

Stefano Fedele, Stefano Fedele

Abstract

The World Health Organization has clearly identified prevention and early detection as major objectives in the control of the oral cancer burden worldwide. At the present time, screening of oral cancer and its pre-invasive intra-epithelial stages, as well as its early detection, is still largely based on visual examination of the mouth. There is strong available evidence to suggest that visual inspection of the oral mucosa is effective in reducing mortality from oral cancer in individuals exposed to risk factors. Simple visual examination, however, is well known to be limited by subjective interpretation and by the potential, albeit rare, occurrence of dysplasia and early OSCC within areas of normal-looking oral mucosa. As a consequence, adjunctive techniques have been suggested to increase our ability to differentiate between benign abnormalities and dysplastic/malignant changes as well as to identify areas of dysplasia/early OSCC that are not visible to naked eye. These include the use of toluidine blue, brush biopsy, chemiluminescence and tissue autofluorescence. The present paper reviews the evidence supporting the efficacy of the aforementioned techniques in improving the identification of dysplastic/malignant changes of the oral mucosa. We conclude that available studies have shown promising results, but strong evidence to support the use of oral cancer diagnostic aids is still lacking. Further research with clear objectives, well-defined population cohorts, and sound methodology is strongly required.

References

    1. International Agency for Research on Cancer – World Health Organization The GLOBOCAN 2002 database
    1. Mignogna MD, Fedele S, Lo Russo L. The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev. 2004;13:139–142. doi: 10.1097/00008469-200404000-00008.
    1. Gloeckler Ries LA, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, eds . NIH publication no 97-2789. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, US; 1997. SEER cancer statistics review, 1973–1994.
    1. Mignogna MD, Fedele S, Lo Russo L, Ruoppo E, Lo Muzio L. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev. 2002;11:205–208. doi: 10.1097/00008469-200206000-00002.
    1. Mashberg A. Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration. Oral Oncol. 2000;36:253–255. doi: 10.1016/S1368-8375(00)00006-3.
    1. Mignogna MD, Fedele S, Lo Russo L, Ruoppo E, Lo Muzio L. Oral and pharyngeal cancer: lack of prevention and early detection by health care providers. Eur J Cancer Prev. 2001;10:381–3838. doi: 10.1097/00008469-200108000-00014.
    1. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol. 2004;40:120–130. doi: 10.1016/j.oraloncology.2003.08.001.
    1. Mignogna MD, Fedele S, Lo Russo L, Mignogna C, de Rosa G, Porter SR. Field cancerization in oral lichen planus. Eur J Surg Oncol. 2007;33:383–389. doi: 10.1016/j.ejso.2006.09.028.
    1. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33:1113–1116.
    1. Rajendran R. Oral submucous fibrosis: etiology, pathogenesis, and future research. Bull World Health Organ. 1994;72:985–996.
    1. Burzynski N, Firriolo FJ, Butters JM, Sorrell CL. Evaluation of oral cancer screening. J Cancer Educ. 1997;12:95–99.
    1. Eaton L. World cancer rates set to double by 2020. BMJ. 2003;326:728. doi: 10.1136/bmj.326.7392.728/a.
    1. IARC-WHO . In: World Cancer Report. Stewart BW, Kleihues P, editor. International Agency for Research on Cancer and World Health Organization. Geneve: Suisse; 2002.
    1. Allison P, Locker D, Feine JS. The role of diagnostic delays in the prognosis of oral cancer: a review of the literature. Oral Oncol. 1998;34:161–170. doi: 10.1016/S1368-8375(97)00071-7.
    1. Smart CR. Screening for cancer of the aerodigestive tract. Cancer. 1993;72:1061–1065. doi: 10.1002/1097-0142(19930801)72:3+<1061::AID-CNCR2820721320>;2-1.
    1. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B, Trivandrum Oral Cancer Screening Study Group Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365:1927–33. doi: 10.1016/S0140-6736(05)66658-5.
    1. Mignogna MD, Fedele S. Oral cancer screening: 5 minutes to save a life. Lancet. 2005;365:1905–1906. doi: 10.1016/S0140-6736(05)66635-4.
    1. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44:10–22. doi: 10.1016/j.oraloncology.2007.06.011.
    1. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc. 2008;139:896–905.
    1. Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis. Int J Oral Maxillofac Surg. 2002;31:262–266. doi: 10.1054/ijom.2002.0220.
    1. Frist S. The oral brush biopsy: separating fact from fiction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:654–5. doi: 10.1016/j.tripleo.2003.11.002.
    1. Eisen D. Brush biopsy 'saves lives'. J Am Dent Assoc. 2002;133:688–692.
    1. Eisen D, Frist S. The relevance of the high positive predictive value of the oral brush biopsy. Oral Oncol. 2005;41:753–755. doi: 10.1016/j.oraloncology.2004.10.004.
    1. Sciubba JJ. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445–1457.
    1. Svirsky JA, Burns JC, Carpenter WM, Cohen DM, Bhattacharyya I, Fantasia JE, Lederman DA, Lynch DP, Sciubba JJ, Zunt SL. Comparison of computer-assisted brush biopsy results with follow up scalpel biopsy and histology. Gen Dent. 2002;50:500–503.
    1. Poate TW, Buchanan JA, Hodgson TA, Speight PM, Barrett AW, Moles DR, Scully C, Porter SR. An audit of the efficacy of the oral brush biopsy technique in a specialist Oral Medicine unit. Oral Oncol. 2004;40:829–834. doi: 10.1016/j.oraloncology.2004.02.005.
    1. Potter TJ, Summerlin DJ, Campbell JH. Oral malignancies associated with negative transepithelial brush biopsy. J Oral Maxillofac Surg. 2003;61:674–677. doi: 10.1053/joms.2003.50136.
    1. Rick GM. Oral brush biopsy: the problem of false positives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:252. doi: 10.1016/S1079-2104(03)00362-7.
    1. Scheifele C, Schmidt-Westhausen AM, Dietrich T, Reichart PA. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824–828. doi: 10.1016/j.oraloncology.2004.02.004.
    1. Mashberg A. Final evaluation of tolonium chloride rinse for screening of high-risk patients with asymptomatic squamous carcinoma. J Am Dent Assoc. 1983;106:319–323.
    1. Epstein JB, Feldman R, Dolor RJ, Porter SR. The utility of tolonium chloride rinse in the diagnosis of recurrent or second primary cancers in patients with prior upper aerodigestive tract cancer. Head Neck. 2003;25:911–921. doi: 10.1002/hed.10309.
    1. Warnakulasuriya KA, Johnson NW. Sensitivity and specificity of OraScan (R) toluidine blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med. 1996;25:97–103. doi: 10.1111/j.1600-0714.1996.tb00201.x.
    1. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:535–540. doi: 10.1067/moe.2001.112949.
    1. Martin IC, Kerawala CJ, Reed M. The application of toluidine blue as a diagnostic adjunct in the detection of epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:444–446. doi: 10.1016/S1079-2104(98)90071-3.
    1. Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M, Scully C. Toluidine blue uptake in potentially malignant oral lesions in vivo: clinical and histological assessment. Oral Oncol. 2006;42:89–95. doi: 10.1016/j.oraloncology.2005.06.016.
    1. Zhang L, Williams M, Poh CF, Laronde D, Epstein JB, Durham S, Nakamura H, Berean K, Hovan A, Le ND, Hislop G, Priddy R, Hay J, Lam WL, Rosin MP. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005;65:8017–8021.
    1. Ram S, Siar CH. Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. Int J Oral Maxillofac Surg. 2005;34:521–527. doi: 10.1016/j.ijom.2004.10.008.
    1. Epstein JB, Gorsky M, Lonky S, Silverman S, Jr, Epstein JD, Bride M. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. Spec Care Dentist. 2006;26:171–174. doi: 10.1111/j.1754-4505.2006.tb01720.x.
    1. Kerr AR, Sirois DA, Epstein JB. Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. J Clin Dent. 2006;17:59–63.
    1. Farah CS, McCullough MJ. A pilot case control study on the efficacy of acetic acid wash and chemiluminescent illumination (ViziLitetrade mark) in the visualisation of oral mucosal white lesions. Oral Oncol. 2007;43:820–824. doi: 10.1016/j.oraloncology.2006.10.005.
    1. Oh ES, Laskin DM. Efficacy of the ViziLite system in the identification of oral lesions. J Oral Maxillofac Surg. 2007;65:424–426. doi: 10.1016/j.joms.2006.10.055.
    1. Epstein JB, Silverman S, Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol. 2008;44:538–544. doi: 10.1016/j.oraloncology.2007.08.011.
    1. De Veld DC, Witjes MJ, Sterenborg HJ, Roodenburg JL. The status of in vivo autofluorescence spectroscopy and imaging for oral oncology. Oral Oncol. 2005;41:117–131. doi: 10.1016/j.oraloncology.2004.07.007.
    1. Onizawa K, Saginoya H, Furuya Y, Yoshida H. Fluorescence photography as a diagnostic method for oral cancer. Cancer Lett. 1996;108:61–66. doi: 10.1016/S0304-3835(96)04388-1.
    1. Schantz SP, Kolli V, Savage HE, Yu G, Shah JP, Harris DE, Katz A, Alfano RR, Huvos AG. In vivo native cellular fluorescence and histological characteristics of head and neck cancer. Clin Cancer Res. 1998;4:1177–1182.
    1. Onizawa K, Saginoya H, Furuya Y, Yoshida H, Fukuda H. Usefulness of fluorescence photography for diagnosis of oral cancer. Int J Oral Maxillofac Surg. 1999;28:206–210. doi: 10.1016/S0901-5027(99)80140-4.
    1. Poh CF, Ng SP, Williams PM, Zhang L, Laronde DM, Lane P, Macaulay C, Rosin MP. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck. 2007;29:71–76. doi: 10.1002/hed.20468.
    1. Rosin MP, Poh CF, Guillard M, Williams PM, Zhang L, MacaUlay C. Visualization and other emerging technologies as change makers for oral cancer prevention. Ann N Y Acad Sci. 2007;1098:167–183. doi: 10.1196/annals.1384.039.
    1. Inaguma M, Hashimoto K. Porphyrin-like fluorescence in oral cancer: In vivo fluorescence spectral characterization of lesions by use of a near-ultraviolet excited autofluorescence diagnosis system and separation of fluorescent extracts by capillary electrophoresis. Cancer. 1999;86:2201–2211. doi: 10.1002/(SICI)1097-0142(19991201)86:11<2201::AID-CNCR5>;2-9.
    1. Petersen PE. Oral cancer prevention and control – The approach of the World Health Organization. Oral Oncol. 2008.
    1. Campo-Trapero J, Cano-Sánchez J, Palacios-Sánchez B, Sánchez-Gutierrez JJ, González-Moles MA, Bascones-Martínez A. Update on molecular pathology in oral cancer and precancer. Anticancer Res. 2008;28:1197–1205.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi